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Purpose: Acute aortic occlusion with subsequent ischemia/reperfusion ( I /R)  of the lower 
extremities i known to predispose to hmg injury. The pathophysiologic mechanisms of 
this injury are not dear. In the present study, we studied the role of tumor necrosis factor 
(TNF) and nitric oxide (NO) in lung injury caused by lower extremity I/1L 
Methods: A rat model in which the infrarenal aorta was cross-clamped for 3 hours followed by 
1 hour of reperfusion was used. The rats were randomized into five groups: group 1, aorta 
exposed but not damped; group 2, aorta clamped for 3 hours, followed by 1 hour of 
reperfusion; group 3, 1 mg/kg dexamethasone administered b fore the aorta was clamped; 
group 4, 25 mg aminoguanidine, a specific inducible NO synthase'(iNOS) inhibitor, admin- 
istered before the aorta was damped; and group 5, 2 mg/kg TNFbw a PEG-ylated imeric 
form of the high-affinity p55 TNF receptor I (RI), administered before the aorta was 
damped. NO concentration i the exhaled gas (ENO) was measured, as an index of NO 
production by the lung, in 30 minute intervals during I / IL  Serial arterial blood samples for 
TNF assay were obtained uring the course of the experiment. At the end of the experiment, 
the lungs were removed and histologically examined for evidence of injury. 
Results: ENO in group 2 increased from 0.7 -+ 0.3 ppb at baseline to 54.3 -+ 7.5 ppb at 
the end ofischemia nd remained stable during reperfusion (54.6 -+ 8.5 ppb at the end of 
reperfusion). ENO production was blocked by aminoguanidine, by dexamethasone, and 
by TNFbv given before aortic occlusion. Serum TNF in groups 2, 3, and 4 increased 
rapidly during early ischemia, reaching its peak value 60 minutes after occlusion of the 
aorta, then gradually declined to baseline levels at the end ofischemia, and remained low 
during reperfusion. TNFbv decreased serum TNF concentration significantly when it was 
given before aortic occlusion. Histologic examination of the lungs at the end of the 
experiment revealed that aminoguanidine, dexamethasone, and TNFbv had a protective 
effect on the lungs. 
Conclusions: Serum TNF increases rapidly during lower extremity ischemia nd causes 
increased production of NO from the lung by upregulating iNOS. Increased NO is 
associated with more severe lung injury, and iNOS blockade has beneficial effects on the 
lung. TNF blockade before ischemia decreases NO production by the lung and attenuates 
lung injury. ENO can be used as an early marker of lung injury caused by lower extremity 
I/R_ (J Vasc Surg 1997;26:647-56.) 
Lung injury is lmown to occur after procedures 
that involve temporary occlusion of  the aorta and 
From the Department of Surgery and the Department of Pathol- 
ogy, State University of New York Health Science Center. 
Presented in part at the Twenty-second Annual Meeting of the 
Peripheral Vascular Surgical Society, Boston, Mass., May 31, 1997. 
Reprint requests: Daniel J. McGraw, MD, Department of Surgery, 
SUNY Health Science Center, 750 East Adams St., Syracuse, 
NY 13210. 
Copyright © 1997 by The Society for Vascular Surgery and Inter- 
national Society for Cardiovascular Surgery, North American 
Chapter. 
0741-5214/97/$5.00 + 0 24/1/84436 
subsequent ischemia/reperfusion ( I /R )  of the lower 
extremities. Extensive clinical and experimental work 
has been conducted to study the mechanism(s) re- 
sponsible for this injury to better identify the primary 
targets for therapeutic ntervention. Stallone and co- 
workers, 1 using a dog model and a very carefully 
planned experimental protocol, showed that in addi- 
tion to microemboli released into the systemic ve- 
nous circulation during reperfusion, other factors 
were apparently involved in the lung injury process, 
which could be effectively eliminated by shunting all 
the venous return from the lower extremities 
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through the liver. Welbourn et al. 2 speculated a me- 
diator role for tumor necrosis factor (TNF) and 
showed that TNF antiserum exerts a protective ffect 
on the lung when it is administered 30 minutes 
before reperfusion. In the same study, serum TNF 
concentration was measured during reperfusion and 
was found to be elevated 4 hours after the blood 
supply to the lower extremities was restored. The 
authors uggested that TNF mediates lung injury by 
activating polymorphonuclear neutrophils (PMNs) 
and enhancing their sequestration to the lung. 
PMNs have been shown to have a central role in lung 
injury caused by I /R  of the lower extremities, and 
their depletion exerts a protective ffect o the lung 
under these conditions, a In clinical settings, tempo- 
rary ischemia of the lower extremities may result in 
shock and acute lung injury that requires inotropic 
and ventilatory support. It is still unclear, however, 
whether the injury process tarts during ischemia or 
whether it is a "washout" phenomenon caused by 
the release of humoral mediators and activated 
PMNs from the ischemic region to the systemic ir- 
culation during reperfusion. 
Endogenous nitric oxide (NO) is present in the 
exhaled gas of human beings, rats, rabbits, and other 
animals. 4 NO is synthesized via the oxidation of 
L-arginine by a family of NO synthases that are either 
constitutive and calcium dependent (eNOS), or in- 
ducible and calcium independent (iNOS). The en- 
dogenous production of NO plays a vital role in the 
regulation of physiologic processes uch as blood 
vessel tone, in host defense and immunity, as well as 
in the modulation of the inflammatory esponse, 5 
Several recent studies have shown that he concentra- 
tion of NO in the exhaled gas (ENO) increases dur- 
ing inflammatory conditions uch as sepsis, adult 
respiratory distress syndrome (ARDS), and asth- 
ma. 6-1° The increase in ENO is a result of upregula- 
tion of iNOS by inflammatory c tokines. 11,12 This 
enzyme (iNOS) is responsible for sustained NO pro- 
duction at higher concentrations forprolonged peri- 
ods of time, from a variety of cell types, when in- 
duced by stimuli such as cytoldnes. 6,1a Robbins et 
al. 12 showed that many cells in the lung (alveolar 
macrophages, airway and alveolar epithelial ceils, pul- 
monary artery endothelial cells, and smooth muscle 
cells) are capable of expressing iNOS and releasing 
NO in response to stimulation by cytokines. ENO 
reflects NO production from the lung and has been 
proposed as an early index of lung inflammation 
caused by sepsis. 6 
In the present study, we measured ENO and 
TNF during a 3 hour aortic occlusion, with subse- 
quent lower extremity ischemia, followed by I hour 
of reperfusion, in a rat model. Our hypothesis was 
that TNF generated uring acute ischemia of the 
lower extremities results in upregulation of iNOS 
and subsequent increased NO production in the 
lung, as well as in other remote organs. We also 
studied the effect of pharmacologic nterventions 
that block TNF action and NO synthesis on lung 
injury. 
MATERIALS AND METHODS 
Animal care complied with the "Principles of 
Laboratory Animal Care" as formulated by the Na- 
tional Society fbr Medical Research and the Guide for 
the Care and Use of Laboratory Animals (NIH publi- 
cation No. 86-23, revised 1985). After approval by 
the Institutional Committee for Human Use of Ani- 
mals, 40 adult male Sprague-Dawley rats weighing 
350 to 460 g and fasted overnight were anesthetized 
with an intraperitoneal injection of pentobarbital so- 
dium (50 mg/kg). Carotid and pulmonary arterial 
catheters were inserted for pressure monitoring, and 
a jugular venous line was established for intravenous 
fluid infusion through the same neck incision. A 
tracheostomy was then performed, and the rats were 
ventilated with room air using a rodent ventilator 
(model 683, Harvard Apparatus, South Natick, 
Mass.). The animals were then given heparin (I000 
units/kg), and baseline (BL) measurements of mean 
arterial pressure (MAP), mean pulmonary artery 
pressure (MPAP), and pulmonary airway pressure 
(PAW) were obtained. The animals were maintained 
in anesthesia with continuous intravenous infusion of 
pentobarbital sodium at 4 mg/kg/hr.  All animals 
were given lactated Ringer's olution (Baxters, Deer- 
field, Ill.) at a constant rate (4 ml/kg/hr) during the 
entire course of the experiment. Systemic and pup 
monary arterial pressure, as well as pulmonary airway 
pressure, were recorded continuously (8890A, 
Hewlett-Packard Chart recorder, Andover, Mass.). 
ENO was measured using a chemiluminescence ana- 
lyzer (Sievers 270 B, Boulder, Colo.). A 1 L polyvi- 
nyl bag was connected to the expiratory port of the 
ventilator, and the expiratory gas from the rat was 
collected for 2 minutes. The bag was then connected 
to the NO analyzer, and the mean NO concentration 
in the bag was recorded in parts per billion as an 
index of ENO concentration. ENO was measured 
before aortic occlusion (BL) and thereafter in 30 
minutes intervals during ischemia nd reperfusion. 
The NO analyzer was calibrated aily using nitrogen 
for a zero and a mixture of 248 ppb NO in nitrogen. 
Room air was monitored aily and when the NO 
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Fig. 1. Changes in TNF concentration during I/R. Groups 2 (n = 9) and 4 (n = 7) had 
significantly higher peak serum TNF concentrations (p < 0.05) compared with groups 1 (n = 
8) and 5 (n = 9). Group 3 (n = 7) had lower peak serum TNF concentration compared with 
groups 2 and 4 as well, but difference did not reach statistical significance. Values are presented 
as mean _+ SEM. 
concentration exceeded 5 ppb, the rats were venti- 
lated with compressed air from a gas cylinder that 
had zero NO. This insured that the results were not 
influenced by fluctuation in room air NO concentra- 
tion as a result of  environmental factors. Because 
several other factors (including pH,  end-expiratory 
pressure, and hypoxia) also influence ENO, 14 every 
attempt was made to maintain constant conditions 
during the experiments. 
The infrarenal aorta was exposed through a mid- 
line abdominal incision, and the rats were random- 
ized into five groups: 
• In group 1 (control), the aorta was exposed but 
not cross-clamped, and the animal was observed 
for four hours (n = 8). 
• In group 2 (cross-clamp), the aorta was cross- 
clamped just above the bifurcation with special 
vascular clips for 3 hours, followed by 1 hour of 
reperfusion (n = 9). 
• In group 3 (steroids), animals were pretreated 
with 1 mg/kg  dexamethasone (American Regent 
Laboratories, Shirley, N.Y.) before aortic cross- 
clamping (n = 7). 
• In group 4 (AG), animals were given 25 mg ami- 
noguanidine (Sigma Chemical, St. Louis), a spe- 
cific iNOS inhibitor, before the aortic clamp was 
applied. 
• In group 5 (TNFbp), animals were given 2 mg/kg  
TNFbp (Amgen Inc., Boulder, Colo.), a PEG- 
ylated dimeric form of the high-a~inity TNF-RI, 
before the aortic clamp was applied. 
Animals in groups 3, 4, and 5 were subjected to 
the same I /R  time as the animals in group 2. 
MAP, MPAP, PAW, and ENO were measured in 
30 minute intervals during the ischemia nd reperfu- 
sion phases. Arterial blood samples were obtained for 
blood gas (ABG) analysis and TNF assay. ABGs were 
measured at BL, after 90 and 180 minutes of  isch- 
emia, and 30 minutes after reperfusion. Serum TNF 
levels were measured at BL, after 60, 90, 120, and 
180 minutes ofischemia, and 30 minutes after reper- 
fusion. Blood samples (0.5 ml) were withdrawn for 
TNF measurement, and the blood was replaced with 
an equal volume of fluid. The arterial blood samples 
obtained for TNF assay were centrifuged immedi- 
ately at 10,000 to 12,000 r /min  for 30 to 60 sec- 
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Fig. 2. NO concentration in exhaled gas (ENO) during I/R. In groups 1 (n = 8), 3 (n = 7), 
4 (n = 7), and 5 (n = 9), ENO reached significantly higher levels compared with baseline (p < 
0.05) at end ofischemia. There was no significant difference in ENO levels among these groups 
at any point during the course of experiment. In contrast, ENO in group 2 (n = 9) reached 
significantly higher levels compared with baseline (p < 0.05) at 1 hour ofischemia, and at the 
end of ischemia this difference was extremely significant (p < 0.001). Group 2 ENO was 
significantly higher (p < 0.01) compared with rest of groups at 1 hour ischemia nd for the rest 
of experiment. Values are presented as mean _+ SEM. 
onds, and the serum was collected and stored at 
-70 ° C until assayed. All TNF determinations were 
performed at the same time by an independent inves 
tigator who was blinded to the study. A TNF immu- 
noreactive assay, using an enzyme-linked immuno- 
absorbent system containing a hamster antimouse 
TNF-c~ antibody (Genzyme, Boston, Mass.) was 
used. The results were analyzed spectrophotometri- 
cally and expressed as pg/ml .  At the end of the 
experiment, the animals were ldlled by an intrave- 
nous overdose of pentobarbital sodium. The lungs 
were then removed and immersion-fixed in formalin. 
Fixed specimens were paraffin-embedded, sectioned 
in 4 Ixm pieces, and stained with routine hematoxy- 
lin-eosin stain. The specimens were examined by the 
same pathologist who was blinded to the study. At 
least two different sections of each specimen were 
examined to accurately determine the degree of in- 
jury. Lung injury was rated with a semiquantitative 
score based on congestion, interstitial edema, PMN 
infiltration, and airspace hemorrhage, as follows: 0, 
no changes; 1+, focal, mild, subtle changes; 2+,  
multifocal mild changes; 3+, multifocal prominent 
changes; and 4+,  extensive prominent changes. 
The results are presented as means _+ standard 
error of  mean (SEM). Statistical analysis was per- 
formed using analysis of variance for repeated mea- 
sures and Bonferoni test for post hoc paired compar  
isons, and a p value less than 0.05 was considered 
significant. 
RESULTS 
The changes in serum TNF concentration i the 
five groups are shown in Fig. 1. The TNF concentra- 
tion rose markedly in groups 2, 3, and 4, reaching 
peak values at 60 minutes after the aortic clamp was 
applied, and thereafter gradually declined to baseline 
levels by the end of ischemia. Peak values of TNF in 
groups 2 and 4 (2729 _+ 526 pg /ml  and 3057 -+ 
1625 pg/ml ,  respectively) were higher than peal~ 
values in group 3 (1809 + 463 pg/ml) ,  but this 
difference did not reach statistical significance. Dur- 
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Fig. 3. MAP changes during I/R. There was a gradual decrease inMAP during ischemia in all 
five groups, with further drop at reperfusion (p < 0.05). No significant difference was seen 
among roups at any point during the course of experiment; note, however, that group 3 had a 
more stable course during ischemia, although differences were not statistically significant. 
Values are presented as mean _+ SEM. 
ing reperfusion, TNF concentration remained low in 
these three groups. Serum TNF in group 5 also 
increased uring the first 60 minutes ofischemia nd 
remained at approximately the same level through- 
out ischemia nd reperfusion. Peak levels of serum 
TNF in this group (568 - 32 pg/ml) were signifi- 
cantly lower compared with peak levels in groups 2 
and 4, indicating that TNFbp effectively binds to 
serum TNF and decreases the concentration of its 
active free form. Group 1 exhibited a peal; value 90 
minutes after the aorta was exposed, and it also 
decreased gradually thereafter to baseline values by 
the end of the experiment. Peak TNF values in group 
1 (1158 + 598 pg/ml) were significantly ower com- 
pared with those in groups 2 and 4 (Fig. i). 
The changes in ENO are shown in Fig. 2. Group 
1 showed a small increase in ENO that started 2 
hours after the aorta was exposed and reached apeak 
value of i7 .9 _+ 2.3 ppb at the end of the experiment. 
In group 2, ENO began to rise immediately; it
reached significantly higher levels (compared with 
baseline) 60 minutes after the aortic clamp was ap- 
plied and continued to rise for the duration of isch- 
emia to a peak value 54.3 -+ 7.5 ppb. During reper- 
fusion, ENO remained stable at the same high levels 
(54.6 _+ 8.5 ppb at the end ofreperfusion). Groups 3 
(steroids), 4 (AG), and 5 (TNFbp) exhibited a 
blunted increase in ENO that started 2 hours after 
ischemia and continued during reperfusion. Peak 
ENO values of 19.2 _+ 4.5, 13.2 + 4.5, and 21.0 _+ 
3.3 ppb were detected at the end of reperfusion in 
groups 3, 4, and 5, respectively. There was no signif- 
icant difference in ENO levels among groups 1, 3, 4, 
and 5 at any point during the course of the experi- 
ments (Fig. 2). ENO levels in group 2 were signifi- 
cantly higher compared with all the other groups 
starting at 60 minutes after ischemia nd remained 
significantly higher until the end ofreperfusion. One 
rat in group 3 was apparently resistant o steroid 
treatment and exhibited a relatively large increase in 
ENO compared with the rest of the animals in the 
group (43.2 ppb at the end of reperfusion compared 
with 19.2 -+ 4.5 ppb that represents he mean value 
for the group). 
MAP (Fig. 3) and MPAP (not shown) decreased 
gradually during the course of the experiment in all 
five groups. The differences among the five groups 
were not statistically significant at any time point 
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Fig. 4. Pco 2 and pH changes during I /R  in the five 
groups. There was no significant difference in Pco 2 among 
groups. Groups 2 (n = 9) and 4 (n = 7) had significantly 
lower pH (p < 0.05) compared with groups 1 (n = 8), 3 
(n = 7), and 5 (n = 9) during reperfusion, indicating 
development of metabolic acidosis, which was worse in 
group 2. Values are presented as mean + SEM. 
during the experiment. PAW did not change signifi- 
cantly in all five groups (data not shown). The pH 
remained unchanged throughout the experiments in
groups 1, 3, and 5. In contrast, in groups 2 and 4, 
pH decreased significantly during reperfusion, indi- 
cating a degree of metabolic acidosis, which was 
greater in group 2 (Fig. 4). l~co 2 gradually decreased 
(Fig. 4) and Po  2 increased (data not shown) in all five 
groups, without any significant difference among 
them during the experiment. 
Histologic evaluation revealed significant differ- 
ences in the degree of lung injury in the five groups 
(Fig. 5). Groups 1, 3, 4, and 5 had lesions ranging 
from 0 to 3+, with average injury scores of 1.33, 
1.67, 1.50, and 1.67, respectively. Group 2 exhibited 
extensive, prominent histologic changes ranging 
from 2+ to 4+ and an average injury score of 2.75 
(Fig. 6). The rat with the high ENO level in group 3 
had the most severe lung injury in the group despite 
treatment with steroids. 
DISCUSSION 
In the present study we demonstrated that (1) 
acute ischemia of the lower extremities in rats results 
in a significant increase in serum TNF concentration 
and a subsequent increase in NO production from 
the lung; and (2) TNF and NO are significant deter- 
minants of the lung injury process that is caused by 
lower extremity I /R.  
TNF is known to be a mediator in several inflam- 
matory conditions, including sepsis. TNF is gener- 
ated by rapid transcription and translation and is not 
stored intracellularly in significant amounts) s Pro- 
duction of active TNF from macrophages occurs 
within 15 minutes after exposure to an inflammatory 
stimulus. 16 Activated macrophages and monocytes 
are the primary source of TNF in pathologic ondi- 
tions, is In the study by Welbourn et al., 2 it was 
postulated that lower extremity I /R  induces TNF 
production, but the exact cells responsible were not 
identified. The authors reported a small increase in 
serum TNF after 4 hours of reperfusion in some 
animals but no measurable TNF at the end of the 
4-hour tourniquet ischemia or earlier in reperfusion. 
Sternbergh et al.,17 using isolated rat hindlimbs, 
showed that TNF is generated by the ischemic ex- 
tremities and pointed to tissue macrophages and en- 
dothelial cells as the presumptive sites of its origin. 
Peal< TNF levels in that study were measured 1.5 
minutes after flow to the isolated extremities was 
restored, with subsequent return to baseline levels 
within 10 minutes. The authors suggested hat this 
was a result of washout of TNF generated uring 
ischemia. TNF production was undetectable during 
reperfusion in both these studies. Our results are in 
agreement with these reports. We observed a signifi- 
cant increase in serum TNF concentration during the 
first hour in all four groups that were subjected to 
lower extremity ischemia. Peak TNF concentrations 
in groups 2, 3, and 4 were measured 60 minutes after 
the aortic clamp was applied, and by the end of the 3 
hour ischemia period, TNF had returned to baseline 
value. In group 5, serum TNF also increased uring 
the first 60 minutes of ischemia but to significantly 
lower levels compared with groups 2, 3, and 4, indi- 
cating that TNF6p significantly decreased active 
TNF. TNFbp is a PEG-ylated dimeric form of the 
high-affinity p55 TNF-R> Administration of phar- 
macologic doses of this compound in models of 
endotoxin shock results in lower levels of serum TNF 
that remain active for longer periods of time. 18 These 
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Fig. 5. Histologic pictures of lungs with different degrees of injury (routine hematoxylin-eosin 
stain; original magnification, 20×). A, 0; B, 1+; C, 2+; D, 3+; E, 4+ (see text for 
description). Note progressively increasing vascular congestion and cellularity of lung intersti- 
tium characterizing more severe forms ofinjury. Also note that inlungs with injury score of 4+ 
there is evidence of alveolar flooding, indicating pulmonary edema. 
reports were entirely confirmed by our measure- 
ments (Fig. 1). Because in our model only the arterial 
blood flow to the lower extremities was blocked, 
whereas the venous and lymphatic return were main- 
tained open during ischemia, TNF generated from 
the ischemic lower extremities could enter the sys- 
temic circulation and exert its effects on remote or- 
gans. The differences in experimental design and in 
the timing of blood sampling may explain the vari- 
ability in the TNF levels reported in other studies at 
different points during the course of I /R.  
Experimentally, injection of exogenous TNF 
causes lung injury characterized by PMN sequestra- 
tion in pulmonary microvasculature, increased endo- 
thelial permeability, and interstitial edema? 9,2° 
These changes resemble those seen after lower ex- 
tremity I /R.  2 Both injuries arc PMN-depcndent and 
can be attenuated by prior depletion of circulating 
PMNs? ,2° TNF is capable of' inducing prolonged 
activation of PMNs with generation and release of 
superoxide ions and granular enzymes. 21,22 This re- 
quires adhesion of PMNs to the endothelium, a pro- 
cess that is also stimulated by TNF. 2 That peak TNF 
concentrations are seen early during ischemia sug- 
gests that lung injury begins during ischemia. This 
theory is supported in Stallone's work ~ by the fact 
that lung changes wcrc seen even in the animal that 
was killed with the aortic clamp still in place. TNF 
acts synergistically with other cytokines to cause up- 
regulation of iNOS and increased NO production in 
cultured lung and bronchial epithelial cells. 1~ Th ie -  
merman et al.23 showed that TNF is a major contrib- 
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Fig. 6. Distribution of lung injury scores in the five groups. Animals in group 2 exhibited the 
most severe histologic changes at end of experiment, whereas aminoguanidine, d xamethasone, 
and TNFbp had a protective effect. Horizontal lines indicate average injury score in each group. 
utor to the LPS-induced upregulation ofiNOS in the 
rat lung (in vivo) and that pretreatment of the animal 
with anti-TNF monoclonal antibody significantly at- 
tenuated iNOS induction. Our results support his 
observation. In group 5, the administration of 
TNFbp before aortic occlusion dramatically de- 
creased serum TNF, thus blocking iNOS upregula- 
tion and NO production. 
ENO reflects NO production by the lung, and its 
levels have been shown to increase during inflamma- 
tory conditions such as sepsis, ARDS, and asth- 
ma. 6q° ENO has not been measured before in the 
setting of lower extremity I /R.  We found that isch- 
emia causes a significant increase in ENO levels, 
which is a result of upregulation of iNOS. NO pro- 
duced in large amounts (as a result of iNOS induc- 
tion) may exert proinflammatory effects, including 
vasodilation, edema, cytotoxicity, and the mediation 
of cytokine-dependent processes. 5 Several studies 
have shown that NO is responsible for the cytotoxic 
action of macrophages activated by microorganisms 
or their products. 2426 The cytotoxic effects of NO 
are thought o be a result of its capacity to react with 
iron-containing enzymes of the respiratory cycle 
(e.g., aconitase and complexes I and II of the mito- 
chondrial respiratory chain), thus inhibiting oxida- 
tive phosphorylation. 5,262s In addition, NO reacts 
with and depletes intracellular glutathione, thus in- 
creasing susceptibility to oxidant stress, ,29 Finally, 
NO can react with other free radicals uch as supcr- 
oxide anion (0  2- ) to generate molecules uch as 
peroxynitritc (-OONO) that enhance its cytotoxici- 
ty. s,3° Although the above data suggest, a potential 
direct cytotoxic effect of NO in different tissues, there 
is significant controversy in current literature con- 
cerning its role in inflammatory conditions. NO has 
been reported to inhibit platelet aggregation and 
adhesion to endothelial monolayers, s,31,32 as well as 
PMN aggregation 5,33 and adhesion to endotheli- 
um, s,34,3s astep required early in the development of
PMN-mediated inflammatory processes. In addition, ,
NO has also bcen shown to inhibit thc production of 
0 2- by activated PMNs. 33,36 Abdih et al.37 showed 
that L-NAME, an L-arginine analogue, enhanced 
PMN adhesion and potentiated microvascular leak in 
the lungs of rats that had been subjected to lower 
extremity I /R.  Similar results were reported by 
Terada et al. 38 in rats that were subjected to intestinal 
I /R.  Based on these observations, inhaled NO has 
been used in the treatment of lung diseases associ- 
ated with PMN sequestration, such as ARDS, but the 
benefits, so far, are inconsistent. 39 
Conversely, NO has also been implicated as a 
significant contributor in acute oxidant lung injury. 4° 
Estrada et al. 41 showed that TNF-induced endothe- 
lial cell damage can be blocked by iNOS inhibitors. It 
is important to note that the cellular regulation of 
NO synthesis a key determinant of its cytotoxicity: 
the picomolar concentrations of NO produced by 
cNOS are nontoxic and sufficient for intracellular 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 4 Tassiopoulos et al. 655 
signaling, and have antiinflammatory properties, 
whereas the high concentrations generated by iNOS 
are potentially proinflammatory and can damage the 
surrounding tissues,  Subsequently, by blocking 
iNOS expression, one can abolish the proinflamma- 
tory action of high NO concentrations, whereas 
eNOS blockade will result in loss of the antiinflam- 
matory properties of low NO concentrations. This 
could explain the diversity existing in receftt litera- 
ture regarding the role of NO in inflammatory con- 
ditions. Aminoguanidine is a specific iNOS inhibitor, 
and its administration effectively blocked iNOS-de- 
pendent NO production in our series. Dexametha- 
sone has also been shown to inhibit iNOS induction 
in the liver and lungs of rats pretreated with endo- 
toxin, in a dose-dependent fashion. 42,43 Kharitonov 
et al. 7 have reported that inhaled glucocorticoids 
decrease ENO in asthmatic patients by inhibiting 
iNOS. Based on the report by Knowles et al., 42 1 
mg/kg dexamethasone i hibits 95% ofiNOS activity 
in the lungs of rats injected with endotoxin, whereas 
it does not affect cNOS activity. This was confirmed 
by our results, which show significantly ower ENO 
levels in the rats that were pretreated with dexameth- 
asone, comparable with the levels seen in the animals 
that were pretreated with aminoguanidine. It is pos- 
sible that dexamethasone blocks iNOS induction by 
both a direct and an indirect (by decreasing TNF 
production) mechanism. 
The histologic evaluation of lungs suggests that 
lower NO levels are associated with lesser degrees of 
lung injury, regardless of the pharmacologic inter- 
vention used to achieve it. Thus specific inhibition of 
iNOS by aminoguanidine, administration f a non- 
specific antiinflammatory agent hat blocks iNOS up- 
regulation (dexamethasone) and TNF blockade, all 
result in decreased production of NO and in lesser 
degrees of lung injury. Of particular interest is the 
fact that the one animal in group 3 that had high 
ENO levels, despite treatment with dexamethasone, 
exhibited the most severe lung injury in the group. 
TNF levels in this animal were comparable with the 
other animals in the group. This finding further cor- 
roborates the notion that NO contributes to lung 
injury process in this animal model. 
CONCLUSION 
Lower extremity ischemia causes a significant in- 
crease in TNF and ENO levels and lung injury that 
appears to be attenuated byTNF blockade and iNOS 
inhibition. The fact that peak TNF and ENO levels 
increase during ischemia may suggest that the lung 
injury process begins once the blood supply to the 
lower extremities is interrupted. Nevertheless, injury 
can also be aggravated during reperfusion, and our 
findings on the histologic hanges can be partially a
result of reperfusion i jury. The extent of histologic 
changes in the lung occurring during ischemia lone 
remains to bestudied. 
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